Our research indicates that Aurora kinase and VEGFR2 inhibitor R1498 shows on-target phenotype in Asian HCC and GC cell and in animal models, and produces significant tumor growth inhibition in vivo, of special note, in human primary derived xenografts with ideal pharmacokinetic profile and therapeutic window. Here, KDR is linked to neoplasm.